The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Ther Adv Urol
; 13: 17562872211043341, 2021.
Article
in En
| MEDLINE
| ID: mdl-34552666
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Ther Adv Urol
Year:
2021
Document type:
Article
Affiliation country:
España
Country of publication:
Reino Unido